Loss of antibody titers and effectiveness of revaccination in post‐chemotherapy pediatric sarcoma patients

Yu, Jennifer; Chou, Alexander J.; Lennox, Alison; Kleiman, Phillip; Wexler, Leonard H.; Meyers, Paul A.; Görlick, Richard

doi:10.1002/pbc.21277

Cited by 22 publications

(16 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are well-established recommendations for reimmunizations after HSCT, but no consensus still exists regarding whether reimmunizations are necessary after standard chemotherapy, and when such reimmunizations should take place (22, 23). A few cohort studies were published to address changes of antibody titers and response to booster vaccine after chemotherapy (24-26). On the basis of our data, we agree with the strategy of reimmunizing each patient who completed chemotherapy only, as well as HSCT recipients.…”

Section: Discussionmentioning

confidence: 99%

Assessment of Serologic Immunity to Diphtheria-Tetanus-Pertussis After Treatment of Korean Pediatric Hematology and Oncology Patients

et al. 2012

View full text Add to dashboard Cite

The aim of this study was to investigate the diphtheria-tetanus-pertussis antibody titers after antineoplastic treatment and to suggest an appropriate vaccination approach for pediatric hemato-oncologic patients. A total of 146 children with either malignancy in remission after cessation of therapy or bone marrow failure were recruited. All children had received routine immunization including diphtheria-tetanus-acellular pertussis vaccination before diagnosis of cancer. The serologic immunity to diphtheria, tetanus and pertussis was classified as: completely protective, partially protective, or non-protective. Non-protective serum antibody titer for diphtheria, tetanus and pertussis was detected in 6.2%, 11.6%, and 62.3% of patients, respectively, and partial protective serum antibody titer for diphtheria, tetanus and pertussis was seen in 37%, 28.1%, and 8.9% of patients. There was no significant correlation between the severity of immune defect and age, gender or underlying disease. Revaccination after antineoplastic therapy showed significantly higher levels of antibody for each vaccine antigen. Our data indicates that a large proportion of children lacked protective serum concentrations of antibodies against diphtheria, tetanus, and pertussis. This suggests that reimmunization of these patients is necessary after completion of antineoplastic treatment. Also, prospective studies should be undertaken with the aim of devising a common strategy of revaccination.

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of Serologic Immunity to Diphtheria-Tetanus-Pertussis After Treatment of Korean Pediatric Hematology and Oncology Patients

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The defects in immunological functioning caused by intensive chemotherapy may adversely affect the immune memory so that it may not be protective in childhood cancer patients. [18] Despite being vaccinated as part of the EPISA, patients have acquired HBV in the paediatric oncology unit at SBAH. [7] Previous studies have shown that HBV immunity declines with age.…”

Section: Discussionmentioning

confidence: 99%

Investigating hepatitis B immunity in patients presenting to a paediatric haematology and oncology unit in South Africa

et al. 2014

View full text Add to dashboard Cite

“…Most authors agree that the interval time of 6–12 months is adequate to achieve a sufficient immune recovery that, in turn, has a key role in determining the response to vaccination [14, 20, 83, 85–88, 91, 95, 96], but some studies have shown good results after reimmunization with inactivated vaccines already at 3 months [87]. …”

Section: Resultsmentioning

confidence: 99%

Guidelines on Vaccinations in Paediatric Haematology and Oncology Patients

Cesaro

Giacchino

Fioredda

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

Objective. Vaccinations are the most important tool to prevent infectious diseases. Chemotherapy-induced immune depression may impact the efficacy of vaccinations in children. Patients and Methods. A panel of experts of the supportive care working group of the Italian Association Paediatric Haematology Oncology (AIEOP) addressed this issue by guidelines on vaccinations in paediatric cancer patients. The literature published between 1980 and 2013 was reviewed. Results and Conclusion. During intensive chemotherapy, vaccination turned out to be effective for hepatitis A and B, whilst vaccinations with toxoid, protein subunits, or bacterial antigens should be postponed to the less intensive phases, to achieve an adequate immune response. Apart from varicella, the administration of live-attenuated-virus vaccines is not recommended during this phase. Family members should remain on recommended vaccination schedules, including toxoid, inactivated vaccine (also poliomyelitis), and live-attenuated vaccines (varicella, measles, mumps, and rubella). By the time of completion of chemotherapy, insufficient serum antibody levels for vaccine-preventable diseases have been reported, while immunological memory appears to be preserved. Once immunological recovery is completed, usually after 6 months, response to booster or vaccination is generally good and allows patients to be protected and also to contribute to herd immunity.

show abstract

Loss of antibody titers and effectiveness of revaccination in post‐chemotherapy pediatric sarcoma patients

Cited by 22 publications

References 19 publications

Assessment of Serologic Immunity to Diphtheria-Tetanus-Pertussis After Treatment of Korean Pediatric Hematology and Oncology Patients

Assessment of Serologic Immunity to Diphtheria-Tetanus-Pertussis After Treatment of Korean Pediatric Hematology and Oncology Patients

Investigating hepatitis B immunity in patients presenting to a paediatric haematology and oncology unit in South Africa

Guidelines on Vaccinations in Paediatric Haematology and Oncology Patients

Contact Info

Product

Resources

About